Patents by Inventor Mikael Dahlström
Mikael Dahlström has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220002297Abstract: The present invention relates to polymorphs of 5-{2-[({8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridine-6-yl}carbonyl)-amino]ethoxy}-5-oxopentanoic acid (X842), more specifically forms A and B of X842. The invention also relates to a process for the preparation of these polymorphs, to pharmaceutical compositions comprising such polymorphs, and to methods for treating or preventing a gastrointestinal inflammatory disease or a gastric acid related disease, comprising administering a pharmaceutical composition comprising such polymorphs.Type: ApplicationFiled: July 1, 2021Publication date: January 6, 2022Inventors: Mikael DAHLSTRÖM, Pingsheng HU, Davide SBARBADA, Matteo ZACCHÈ, Marinus BOUMA
-
Patent number: 10995115Abstract: The present invention relates to a process for the preparation of certain 1,5-benzothiazepine compounds, and in particular to a process for the preparation of elobixibat. The process can be carried out under mild and safe conditions and may be used to prepare elobixibat on an industrial scale. The invention also relates to a process for the preparation of a crystalline monohydrate of elobixibat.Type: GrantFiled: August 20, 2019Date of Patent: May 4, 2021Assignee: Elobix ABInventors: Ganapati G. Bhat, Johnson M. Coutinho, Mikael Dahlström, Michael Lofthagen, Akinori Tatara
-
Publication number: 20200109165Abstract: The present invention relates to a process for the preparation of certain 1,5-benzothiazepine compounds, and in particular to a process for the preparation of elobixibat. The process can be carried out under mild and safe conditions and may be used to prepare elobixibat on an industrial scale. The invention also relates to a process for the preparation of a crystalline monohydrate of elobixibat.Type: ApplicationFiled: August 20, 2019Publication date: April 9, 2020Inventors: Ganapati G. Bhat, Johnson M. Coutinho, Mikael Dahlström, Michael Lofthagen, Akinori Tatara
-
Patent number: 10428109Abstract: The present invention relates to a process for the preparation of certain 1,5-benzothiazepine compounds, and in particular to a process for the preparation of elobixibat. The process can be carried out under mild and safe conditions and may be used to prepare elobixibat on an industrial scale. The invention also relates to a process for the preparation of a crystalline monohydrate of elobixibat.Type: GrantFiled: March 29, 2019Date of Patent: October 1, 2019Assignee: Elobix ABInventors: Ganapati G. Bhat, Johnson M. Coutinho, Mikael Dahlström, Michael Lofthagen, Akinori Tatara
-
Publication number: 20190276493Abstract: The present invention relates to a process for the preparation of certain 1,5-benzothiazepine compounds, and in particular to a process for the preparation of elobixibat. The process can be carried out under mild and safe conditions and may be used to prepare elobixibat on an industrial scale. The invention also relates to a process for the preparation of a crystalline monohydrate of elobixibat.Type: ApplicationFiled: March 29, 2019Publication date: September 12, 2019Inventors: Ganapati G. Bhat, Johnson M. Coutinho, Mikael Dahlström, Michael Lofthagen, Akinori Tatara
-
Patent number: 8993589Abstract: The present invention relates to substituted imidazo [1,2-a]pyridines of formula I where R is —CH2COOH or —COOH, which inhibits exogenously or endogenously stimulated gastric acid secretion and can be used in the prevention and treatment of gastric acid related diseases and gastrointestinal inflammatory diseases.Type: GrantFiled: February 19, 2014Date of Patent: March 31, 2015Inventor: Mikael Dahlström
-
Publication number: 20140235666Abstract: The present invention relates to substituted imidazo [1,2-a]pyridines of formula I where R is —CH2COOH or —COOH, which inhibits exogenously or endogenously stimulated gastric acid secretion and can be used in the prevention and treatment of gastric acid related diseases and gastrointestinal inflammatory diseases.Type: ApplicationFiled: February 19, 2014Publication date: August 21, 2014Inventor: Mikael DAHLSTRÖM
-
Patent number: 7871998Abstract: Compounds of formula (I): (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.Type: GrantFiled: December 21, 2004Date of Patent: January 18, 2011Assignee: AstraZeneca ABInventors: Susanne Alenfalk, Mikael Dahlström, Fana Hunegnaw, Staffan Karlsson, Malin Lemurell, Ann-Margret Lindqvist, Tore Skjäret, Ingemar Starke
-
Patent number: 7560472Abstract: The present invention relates to new salts of the single enantiomers of omeprazole, i.e. salts of (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole ((S)-omeprazole) and (R)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole ((R)-omeprazole) respectively. More specifically, the present invention relates to 1-cyclohexylethyl ammonium salts of the compounds, formed by a reaction of (S)-omeprazole and (R)-omeprazole respectively and 1-cyclohexylethyl amine. The present invention also relates to a process for preparing the compounds of the invention, a pharmaceutical preparation and a method for treatment of gastric related disorders by administering the compounds of the invention.Type: GrantFiled: September 1, 2004Date of Patent: July 14, 2009Assignee: AstraZeneca ABInventors: Mikael Dahlström, Bo Lindqvist
-
Patent number: 7345061Abstract: The present invention relates to new salts of omeprazole and esomeprazole respectively, i.e. salts of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzirnidazole and the (S)-enantiomer thereof. More specifically, the present invention relates to alkylammonium salts of the compounds, formed by a reaction of omeprazole and esomeprazole respectively and an alkylamine with formula NR1R2R3, wherein R1 is a linear, branched, or cyclic C1-C12-alkyl group, and R2 and R3 are hydrogen. The present invention also relates to a process for preparing crystalline salts, a pharmaceutical preparation, and a method for treatment of gastric related disorders by administering the compound of the invention.Type: GrantFiled: March 4, 2003Date of Patent: March 18, 2008Assignee: AstraZeneca ABInventor: Mikael Dahlström
-
Patent number: 7326724Abstract: The present invention relates to new salts of omeprazole and esomeprazole respectively, i.e. salts of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole and the (S)-enantiomer thereof. More specifically, the present invention relates to adamantan ammonium salt of the compounds, formed by a reaction of omeprazole and esomeprazole respectively and adamantan amine. The present invention also relates to a process for preparing the compounds of the invention, a pharmaceutical preparation and a method for treatment of gastric related disorders by administering the compounds of the invention.Type: GrantFiled: September 1, 2004Date of Patent: February 5, 2008Assignee: AstraZeneca ABInventors: Mikael Dahlström, Arne Brändström
-
Publication number: 20070021467Abstract: The present invention relates to new salts of the single enantiomers of omeprazole, i.e. salts of (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole ((S)-omeprazole) and (R)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole ((R)-omeprazole) respectively. More specifically, the present invention relates to 1-cyclohexylethyl ammonium salts of the compounds, formed by a reaction of (S)-omeprazole and (R)-omeprazole respectively and 1-cyclohexylethyl amine. The present invention also relates to a process for preparing the compounds of the invention, a pharmaceutical preparation and a method for treatment of gastric related disorders by administering the compounds of the invention.Type: ApplicationFiled: September 1, 2004Publication date: January 25, 2007Applicant: ASTRAZENECA ABInventors: Mikael Dahlström, Bo Lindqvist
-
Patent number: 6790960Abstract: The present invention relates to novel compounds, and therapeutically acceptable salts thereof of the formula (I), which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.Type: GrantFiled: May 5, 2003Date of Patent: September 14, 2004Assignee: AstraZeneca ABInventors: Kosrat Amin, Mikael Dahlström, Peter Nordberg, Ingemar Starke
-
Patent number: 6613775Abstract: The present invention relates to novel compounds, and therapeutically acceptable salts thereof of the formula (I), which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.Type: GrantFiled: October 22, 1999Date of Patent: September 2, 2003Assignee: AstraZeneca ABInventors: Kosrat Amin, Mikael Dahlström, Peter Nordberg, Ingemar Starke
-
Patent number: 6579884Abstract: The present invention relates to novel compounds, and therapeutically acceptable salts thereof of the formula (I), which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.Type: GrantFiled: October 13, 1999Date of Patent: June 17, 2003Assignee: AstraZeneca ABInventors: Kosrat Amin, Mikael Dahlström, Peter Nordberg, Ingemar Starke
-
Patent number: 6518270Abstract: The present invention relates to heterocyclic compounds of the formula (I), in which the phenyl moiety is substituted with lower alkyl in 2- and 6-position, which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.Type: GrantFiled: February 8, 2000Date of Patent: February 11, 2003Assignee: AstraZeneca ABInventors: Kosrat Amin, Mikael Dahlström, Peter Nordberg, Ingemar Starke
-
Patent number: 6465505Abstract: The present invention relates to benzimidazole derivatives of the formula (I), in which the phenyl moiety is substituted with lower alkyl in 2- and 6-position, which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.Type: GrantFiled: July 17, 1997Date of Patent: October 15, 2002Assignee: AstraZeneca ABInventors: Kosrat Amin, Mikael Dahlström, Peter Nordberg, Ingemar Starke
-
Patent number: 6313137Abstract: The present invention relates to imidazo pyridine derivatives of the formula (I), in which the phenyl moiety is substituted, and in which the imidazo pyridine moiety is substituted with a carboxamide group in 6-position, which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.Type: GrantFiled: June 14, 1999Date of Patent: November 6, 2001Assignee: AstraZeneca ABInventors: Kosrat Amin, Mikael Dahlström, Peter Nordberg, Ingemar Starke
-
Patent number: 6313136Abstract: The present invention relates to imidazo pyridine derivatives of the formula (I), in which the phenyl moiety is substituted, and in which the imidazo pyridine moiety is substituted with a carboxamide group in 6-position, which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.Type: GrantFiled: June 14, 1999Date of Patent: November 6, 2001Assignee: AstraZeneca ABInventors: Kosrat Amin, Mikael Dahlström, Peter Nordberg, Ingemar Starke
-
Patent number: 6265415Abstract: The present invention relates to imidazo pyridine derivatives of the formula (I), in which the phenyl moiety is substituted with lower alkyl in 2- and 6-position, which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.Type: GrantFiled: March 10, 1998Date of Patent: July 24, 2001Assignee: AstraZeneca ABInventors: Kosrat Amin, Mikael Dahlström, Peter Nordberg, Ingemar Starke